SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: IRWIN JAMES FRANKEL who wrote (10089)5/21/2007 11:03:11 AM
From: A.J. Mullen  Respond to of 10280
 
Citigroup declares Xenopex a shot across the bow from coding.
They mention Sepracor's recourse would be to sue, but then say the Medicare Modernization Act "seems to suggest the coding change can't be subject to judicial review." Citigroup are having a conference call today to discuss the effect of the coding change on Xenopex.

They still like Sepr. They've lowered their target from $66 to $60.

Ashley